Voice of America | January 13, 2023
Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown University, told VOA Mandarin, “Most of China’s population has no natural immunity to COVID, and a low vaccination rate. For that reason, an effective treatment like Paxlovid is vital for Chinese citizens and especially for the elderly and vulnerable.”